4/16
09:15 am
bbio
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain [Yahoo! Finance]
Medium
Report
Sentynl Therapeutics Receives MHRA Authorization of NULIBRY® (fosdenopterin) for Treatment of MoCD Type A in Great Britain [Yahoo! Finance]
4/10
07:30 am
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
4/7
01:25 pm
bbio
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Yahoo! Finance]
Neutral
Report
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Yahoo! Finance]
4/7
01:15 pm
bbio
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Neutral
Report
BridgeBio Pharma Presents Cardiac Magnetic Resonance (CMR) Imaging Evidence Consistent with Clinical Improvement Observed in the ATTRibute-CM Phase 3 Study in Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
3/27
08:13 am
bbio
Noetik Appoints Dr. Shafique Virani as Chief Business Officer [Yahoo! Finance]
Low
Report
Noetik Appoints Dr. Shafique Virani as Chief Business Officer [Yahoo! Finance]
3/21
08:00 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Raymond James. They set an "outperform" rating and a $45.00 price target on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) is now covered by analysts at Raymond James. They set an "outperform" rating and a $45.00 price target on the stock.
3/20
08:08 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $35.00 to $45.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at JPMorgan Chase & Co. from $35.00 to $45.00. They now have an "overweight" rating on the stock.
3/20
07:30 am
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
3/19
08:36 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Cantor Fitzgerald from $60.00 to $70.00. They now have an "overweight" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Cantor Fitzgerald from $60.00 to $70.00. They now have an "overweight" rating on the stock.
3/5
11:53 pm
bbio
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
Low
Report
BridgeBio Pharma Announces Pricing of Public Offering of Common Stock
3/5
08:13 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target lowered by analysts at Mizuho from $60.00 to $53.00. They now have a "buy" rating on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target lowered by analysts at Mizuho from $60.00 to $53.00. They now have a "buy" rating on the stock.
3/4
04:17 pm
bbio
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
Medium
Report
BridgeBio Pharma Announces Proposed Public Offering of Common Stock
3/4
08:06 am
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
Medium
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $47.00 price target on the stock.
3/4
02:38 am
bbio
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM [Yahoo! Finance]
Medium
Report
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM [Yahoo! Finance]
3/4
02:30 am
bbio
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
Medium
Report
BridgeBio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM
2/24
09:49 am
bbio
BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
Medium
Report
BridgeBio Pharma Full Year 2023 Earnings: Misses Expectations [Yahoo! Finance]
2/23
12:15 pm
bbio
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Citigroup Inc. from $42.00 to $46.00. They now have a "buy" rating on the stock.
Low
Report
BridgeBio Pharma, Inc. (NASDAQ: BBIO) had its price target raised by analysts at Citigroup Inc. from $42.00 to $46.00. They now have a "buy" rating on the stock.
2/22
08:09 am
bbio
BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials [Yahoo! Finance]
Low
Report
BridgeBio Pharma Inc (BBIO) Reports Q4 and Full Year 2023 Financials, Advances Key Clinical Trials [Yahoo! Finance]
2/22
07:44 am
bbio
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update [Yahoo! Finance]
Low
Report
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update [Yahoo! Finance]
2/22
07:30 am
bbio
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
Low
Report
BridgeBio Pharma Reports Fourth Quarter and Full Year 2023 Financial Results and Business Update
2/15
08:19 am
bbio
Merit Medicine Announces $2M Seed Round to Transform Employer-Sponsored Healthcare with AI-Powered Risk Predictions [Yahoo! Finance]
Medium
Report
Merit Medicine Announces $2M Seed Round to Transform Employer-Sponsored Healthcare with AI-Powered Risk Predictions [Yahoo! Finance]
2/7
07:44 am
bbio
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan [Yahoo! Finance]
Low
Report
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan [Yahoo! Finance]
2/7
07:34 am
bbio
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
Low
Report
BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan
2/6
07:30 am
bbio
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Low
Report
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2/5
07:39 am
bbio
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Yahoo! Finance]
Low
Report
BridgeBio Pharma Announces U.S. Food and Drug Administration (FDA) Acceptance of New Drug Application (NDA) for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) [Yahoo! Finance]